knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 00:48:25 - browse：1

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： The Readout: Amylyx, Alumis, and Lundbeck drug updates

focus

WSS

IVF, abortion rights issues kick off Biden’s State of the Union

WHO recommends second malaria vaccine

Just how do doctors, lawmakers, and the public define abortion?

NEJM study link tiny plastics in blood vessels to heart problems

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Air quality improving but still lags in Black, Hispanic communities

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The drug industry has found itself all alone in Washington

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Anesthesiologist group: stop taking Ozempic before surgery

The problem with charging patients to message their doctors

The high cost of giving birth even with insurance

With Roe v Wade overturned, abortion providers work to adapt

leisure time

Amylyx ALS drug failure raises questions and concerns

Headspace, Meta partner to launch VR meditation app for Quest

Sen. Paul opposes bill to ban Chinese biotechs

Congress extends some pandemic preparedness programs

The biotech scorecard for Q4: 16 stock

European officials brace for rough respiratory virus season

explore

focus

explore

Wikipedia